1차 출처 기록
결정급탑라인 결과
Elicio Therapeutics: 2상 AMPLIFY-7P의 DFS 평가변수 분석, 2026년 상반기 예정
Elicio Therapeutics has observed fewer disease progressions and deaths than projected in its Phase 2 AMPLIFY-7P study for pancreatic cancer. Consequently, the event-driven primary disease-free survival (DFS) endpoint analysis is now anticipated in the first half of 2026. The company's current cash position is expected to support operations through this catalyst and beyond.
핵심 사실
출처 발췌
EX-99.1 2 elicioq325prdraft_111320.htm EX-99.1 elicioq325prdraft_111320 Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates · In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. · Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival (“DFS”); event-driven primary DFS analysis now anticipated in 1H 2026. · Since the beginning of Q3 2025, the Company has raised gross proceeds of app